RT Journal Article
SR Electronic
T1 Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the Comirnaty® COVID-19 vaccine in nursing home residents
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.06.21264607
DO 10.1101/2021.10.06.21264607
A1 Sánchez-Sendra, Beatriz
A1 Albert, Eliseo
A1 Zulaica, Joao
A1 Torres, Ignacio
A1 Giménez, Estela
A1 Botija, Pilar
A1 Beltrán, María José
A1 Rodado, Celia
A1 Geller, Ron
A1 Navarro, David
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264607.abstract
AB Immunosenescence may impact the functionality and breadth of vaccine-elicited humoral immune responses. The ability of sera to neutralize the SARS-CoV-2 spike protein (S) from Beta, Gamma, Delta, and Epsilon variants of concern (VOCs) relative to the ancestral Wuhan-Hu-1 strain was compared in Comirnaty® COVID-19-vaccinated elderly nursing home residents (n=30) or younger individuals (n=18) and non-vaccinated individuals who recovered from severe COVID-19 (n=19). In all groups, some participants lacked NtAb against one or more VOCs, mainly the Beta variant (15-20%). Serum NtAb titers were lowest against the Beta variant followed by Gamma, Epsilon, and Delta variants. Fold change reduction in NtAb titers relative to the ancestral strain was greatest for the Beta variant (6.7-18.8) followed by Gamma (3.6-6.2), Epsilon (2.9-5.8), and Delta (3.5-4.3) variants, regardless of the study group considered. In summary, older age, frailty, and concurrence of co-morbidities had no impact on the serum NtAb activity profile against SARS-CoV-2 VOCs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research work was supported by a grant from the European Commission NextGeneration EU.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by INCLIVA Research Ethics Committee. Informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, (DN), upon reasonable request.